WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H574740
CAS#: 114084-78-5
Description: Ibandronic Acid is a bisphosphonate anti-resorptive agent and bone resorption inhibitor.
Hodoodo Cat#: H574740
Name: Ibandronic Acid
CAS#: 114084-78-5
Chemical Formula: C9H23NO7P2
Exact Mass: 319.10
Molecular Weight: 319.231
Elemental Analysis: C, 33.86; H, 7.26; N, 4.39; O, 35.08; P, 19.41
Synonym: Ibandronic Acid; BPH 24; Ibandronate
IUPAC/Chemical Name: P,P'-[1-Hydroxy-3-(methylpentylamino)propylidene]bisphosphonic Acid
InChi Key: MPBVHIBUJCELCL-UHFFFAOYSA-N
InChi Code: InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
SMILES Code: CCCCCN(CCC(P(O)(O)=O)(P(O)(O)=O)O)C
Appearance: Solid powder
Purity: >95% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 319.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. McCormack PL, Plosker GL. Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer. Drugs. 2006;66(5):711-728. doi:10.2165/00003495-200666050-00011
2. Barrett-Lee P, Casbard A, Abraham J, et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial [published correction appears in Lancet Oncol. 2014 Feb;15(2):e52-3]. Lancet Oncol. 2014;15(1):114-122. doi:10.1016/S1470-2045(13)70539-4